CA2262994A1
(en)
*
|
1996-08-02 |
1998-02-12 |
Ortho-Mcneil Pharmaceutical, Inc. |
Polypeptides having a single covalently bound n-terminal water-soluble polymer
|
US6066673A
(en)
*
|
1998-03-12 |
2000-05-23 |
The Procter & Gamble Company |
Enzyme inhibitors
|
EP1117444A2
(en)
|
1998-10-09 |
2001-07-25 |
The University Of Michigan |
Hydrogels and water soluble polymeric carriers for drug delivery
|
JO2291B1
(en)
*
|
1999-07-02 |
2005-09-12 |
اف . هوفمان لاروش ايه جي |
Erythopintin derivatives
|
ES2327606T3
(en)
|
2000-01-10 |
2009-11-02 |
Maxygen Holdings Ltd |
CONJUGATES OF G-CSF.
|
DE60138364D1
(en)
|
2000-02-11 |
2009-05-28 |
Bayer Healthcare Llc |
CLEANING FACTOR VII OR VIIA CONJUGATE
|
US6586398B1
(en)
*
|
2000-04-07 |
2003-07-01 |
Amgen, Inc. |
Chemically modified novel erythropoietin stimulating protein compositions and methods
|
WO2001087329A1
(en)
|
2000-05-15 |
2001-11-22 |
F. Hoffmann-La Roche Ag |
Liquid pharmaceutical composition containing an erythropoietin derivate
|
RU2003109746A
(en)
*
|
2000-09-08 |
2005-01-27 |
Грифон Терапьютикс, Инк. (Us) |
SYNTHETIC PROTEINS STIMULATING ERYTHROPOESIS
|
YU48703A
(en)
|
2001-02-27 |
2006-05-25 |
Maxygen Aps |
New interferon beta-like molecules
|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
NZ532027A
(en)
*
|
2001-10-10 |
2008-09-26 |
Neose Technologies Inc |
Remodeling and glycoconjugation of peptides
|
DE10209821A1
(en)
|
2002-03-06 |
2003-09-25 |
Biotechnologie Ges Mittelhesse |
Coupling of proteins to a modified polysaccharide
|
DK1517710T3
(en)
|
2002-06-21 |
2011-07-18 |
Novo Nordisk Healthcare Ag |
Pegylated factor VII glycoforms
|
US7459435B2
(en)
|
2002-08-29 |
2008-12-02 |
Hoffmann-La Roche Inc. |
Treatment of disturbances of iron distribution
|
BR0314107A
(en)
|
2002-09-11 |
2005-07-19 |
Fresenius Kabi De Gmbh |
Production method of hydroxyalkyl starch derivatives
|
DE20321793U1
(en)
|
2002-09-11 |
2010-06-02 |
Fresenius Kabi Deutschland Gmbh |
Hydroxyalkyl starch derivatives
|
DE02020425T1
(en)
*
|
2002-09-11 |
2004-07-15 |
Fresenius Kabi Deutschland Gmbh |
Hasylated polypeptides, especially hasylated erythropoietin
|
EP1681303B1
(en)
|
2002-09-11 |
2013-09-04 |
Fresenius Kabi Deutschland GmbH |
HASylated polypeptides, especially HASylated erythropoietin
|
US7459436B2
(en)
|
2002-11-22 |
2008-12-02 |
Hoffmann-La Roche Inc. |
Treatment of disturbances of iron distribution
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
KR20060003862A
(en)
|
2003-03-14 |
2006-01-11 |
네오스 테크놀로지스, 인크. |
Branched water-soluble polymers and their eonjugates
|
AU2004227937B2
(en)
|
2003-03-31 |
2007-09-20 |
Xencor, Inc |
Methods for rational pegylation of proteins
|
US7610156B2
(en)
|
2003-03-31 |
2009-10-27 |
Xencor, Inc. |
Methods for rational pegylation of proteins
|
US7642340B2
(en)
|
2003-03-31 |
2010-01-05 |
Xencor, Inc. |
PEGylated TNF-α variant proteins
|
WO2006127896A2
(en)
|
2005-05-25 |
2006-11-30 |
Neose Technologies, Inc. |
Glycopegylated factor ix
|
US8791070B2
(en)
|
2003-04-09 |
2014-07-29 |
Novo Nordisk A/S |
Glycopegylated factor IX
|
US20070026485A1
(en)
|
2003-04-09 |
2007-02-01 |
Neose Technologies, Inc. |
Glycopegylation methods and proteins/peptides produced by the methods
|
US7074755B2
(en)
|
2003-05-17 |
2006-07-11 |
Centocor, Inc. |
Erythropoietin conjugate compounds with extended half-lives
|
KR20060032140A
(en)
|
2003-05-30 |
2006-04-14 |
센토코 인코포레이티드 |
Formation of novel erythropoietin conjugates using transglutaminase
|
WO2005012484A2
(en)
|
2003-07-25 |
2005-02-10 |
Neose Technologies, Inc. |
Antibody-toxin conjugates
|
JP2007501812A
(en)
*
|
2003-08-08 |
2007-02-01 |
ノボ ノルディスク アクティーゼルスカブ |
Synthesis and application of new structurally well-defined branched polymers as binders for peptides
|
WO2005014655A2
(en)
|
2003-08-08 |
2005-02-17 |
Fresenius Kabi Deutschland Gmbh |
Conjugates of hydroxyalkyl starch and a protein
|
CN102516386A
(en)
|
2003-10-10 |
2012-06-27 |
诺沃挪第克公司 |
Il-21 derivatives
|
EP1675871A2
(en)
|
2003-10-10 |
2006-07-05 |
Xencor Inc. |
Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
|
EP2641611A3
(en)
|
2003-10-17 |
2013-12-18 |
Novo Nordisk A/S |
Combination therapy
|
US20080305992A1
(en)
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
US8633157B2
(en)
|
2003-11-24 |
2014-01-21 |
Novo Nordisk A/S |
Glycopegylated erythropoietin
|
US20060040856A1
(en)
|
2003-12-03 |
2006-02-23 |
Neose Technologies, Inc. |
Glycopegylated factor IX
|
EP1696947B1
(en)
|
2003-12-19 |
2014-02-26 |
F.Hoffmann-La Roche Ag |
Use of erythropoietin in the treatment of disturbances of iron distribution in chronic inflammatory intestinal diseases
|
KR101439880B1
(en)
|
2004-01-08 |
2014-09-12 |
라티오팜 게엠베하 |
O-linked glycosylation of peptides
|
AU2005319099B2
(en)
|
2004-02-02 |
2010-09-16 |
Ambrx, Inc. |
Modified human growth hormone
|
AU2005211362B2
(en)
|
2004-02-02 |
2008-03-13 |
Ambrx, Inc. |
Modified human interferon polypeptides and their uses
|
WO2005092928A1
(en)
|
2004-03-11 |
2005-10-06 |
Fresenius Kabi Deutschland Gmbh |
Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
|
CA2568952C
(en)
|
2004-06-18 |
2019-05-21 |
Ambrx, Inc. |
Novel antigen-binding polypeptides and their uses
|
EP1771066A2
(en)
|
2004-07-13 |
2007-04-11 |
Neose Technologies, Inc. |
Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1
|
US8268967B2
(en)
|
2004-09-10 |
2012-09-18 |
Novo Nordisk A/S |
Glycopegylated interferon α
|
ES2572779T3
(en)
|
2004-10-29 |
2016-06-02 |
Ratiopharm Gmbh |
Remodeling and glucopegilation of Fibroblast Growth Factor (FGF)
|
JP4990792B2
(en)
|
2004-12-22 |
2012-08-01 |
アンブレツクス・インコーポレイテツド |
Compositions of aminoacyl-tRNA synthetases and uses thereof
|
EP1836316A4
(en)
|
2004-12-22 |
2009-07-22 |
Ambrx Inc |
Methods for expression and purification of recombinant human growth hormone
|
NZ555386A
(en)
|
2004-12-22 |
2011-01-28 |
Ambrx Inc |
Formulations of human growth hormone comprising a non-naturally encoded amino acid
|
ES2449195T3
(en)
|
2005-01-10 |
2014-03-18 |
Ratiopharm Gmbh |
Glycopegylated granulocyte colony stimulating factor
|
AU2006222187A1
(en)
*
|
2005-03-11 |
2006-09-14 |
Fresenius Kabi Deutschland Gmbh |
Production of bioactive glycoproteins from inactive starting material by conjugation with hydroxyalkylstarch
|
EP2386571B1
(en)
|
2005-04-08 |
2016-06-01 |
ratiopharm GmbH |
Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
|
ATE529442T1
(en)
|
2005-06-03 |
2011-11-15 |
Ambrx Inc |
IMPROVED HUMAN INTERFERON MOLECULES AND THEIR USES
|
JP5335422B2
(en)
|
2005-06-17 |
2013-11-06 |
ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト |
Selective reduction and derivatization of engineered proteins containing at least one unnatural cysteine
|
US20070105755A1
(en)
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
US20090048440A1
(en)
|
2005-11-03 |
2009-02-19 |
Neose Technologies, Inc. |
Nucleotide Sugar Purification Using Membranes
|
EP1951890A4
(en)
|
2005-11-16 |
2009-06-24 |
Ambrx Inc |
Methods and compositions comprising non-natural amino acids
|
EP2213733A3
(en)
|
2006-05-24 |
2010-12-29 |
Novo Nordisk Health Care AG |
Factor IX analogues having prolonged in vivo half life
|
US9187532B2
(en)
|
2006-07-21 |
2015-11-17 |
Novo Nordisk A/S |
Glycosylation of peptides via O-linked glycosylation sequences
|
CA2659990C
(en)
|
2006-08-04 |
2016-03-22 |
Prolong Pharmaceuticals, Inc. |
Polyethylene glycol erythropoietin conjugates
|
EP2615108B1
(en)
|
2006-09-08 |
2016-10-26 |
Ambrx, Inc. |
Modified human plasma polypeptide or fc scaffolds and thier uses
|
DK2061878T3
(en)
|
2006-09-08 |
2014-04-07 |
Ambrx Inc |
HYBRID SUPPRESSOR TRNA FOR ANIMAL CELLS
|
MX2009002526A
(en)
|
2006-09-08 |
2009-04-16 |
Ambrx Inc |
Suppressor trna transcription in vertebrate cells.
|
EP2054521A4
(en)
|
2006-10-03 |
2012-12-19 |
Novo Nordisk As |
Methods for the purification of polypeptide conjugates
|
BRPI0720282B8
(en)
|
2006-12-15 |
2021-05-25 |
Baxalta GmbH |
protein construction, pharmaceutical composition, and kit
|
ATE554785T1
(en)
|
2007-03-30 |
2012-05-15 |
Ambrx Inc |
MODIFIED FGF-21 POLYPEPTIDES AND THEIR USE
|
CA2682897C
(en)
|
2007-04-03 |
2016-11-22 |
Biogenerix Ag |
Methods of treatment using glycopegylated g-csf
|
WO2008137471A2
(en)
|
2007-05-02 |
2008-11-13 |
Ambrx, Inc. |
Modified interferon beta polypeptides and their uses
|
CN101778859B
(en)
|
2007-06-12 |
2014-03-26 |
诺和诺德公司 |
Improved process for the production of nucleotide sugars
|
CN104689333B
(en)
|
2007-08-27 |
2018-05-29 |
拉蒂奥法姆有限责任公司 |
The liquid preparation of G-CSF conjugates
|
US8207112B2
(en)
|
2007-08-29 |
2012-06-26 |
Biogenerix Ag |
Liquid formulation of G-CSF conjugate
|
EP2930182A1
(en)
|
2007-11-20 |
2015-10-14 |
Ambrx, Inc. |
Modified insulin polypeptides and their uses
|
EP2070951A1
(en)
|
2007-12-14 |
2009-06-17 |
Fresenius Kabi Deutschland GmbH |
Method for producing a hydroxyalkyl starch derivatives with two linkers
|
EP2070950A1
(en)
|
2007-12-14 |
2009-06-17 |
Fresenius Kabi Deutschland GmbH |
Hydroxyalkyl starch derivatives and process for their preparation
|
SG188143A1
(en)
|
2008-02-08 |
2013-03-28 |
Ambrx Inc |
Modified leptin polypeptides and their uses
|
US20130189239A1
(en)
|
2008-02-27 |
2013-07-25 |
Novo Nordisk A/S |
Conjugated Factor VIII Molecules
|
TWI395593B
(en)
|
2008-03-06 |
2013-05-11 |
Halozyme Inc |
In vivo temporal control of activatable matrix-degrading enzymes
|
SG187427A1
(en)
|
2008-04-14 |
2013-02-28 |
Halozyme Inc |
Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
|
TWI394580B
(en)
|
2008-04-28 |
2013-05-01 |
Halozyme Inc |
Super fast-acting insulin compositions
|
US10138283B2
(en)
|
2008-07-23 |
2018-11-27 |
Ambrx, Inc. |
Modified bovine G-CSF polypeptides and their uses
|
MX2011003196A
(en)
|
2008-09-26 |
2011-04-27 |
Ambrx Inc |
Non-natural amino acid replication-dependent microorganisms and vaccines.
|
CN102232085A
(en)
|
2008-09-26 |
2011-11-02 |
Ambrx公司 |
Modified animal erythropoietin polypeptides and their uses
|
KR101546563B1
(en)
|
2008-12-09 |
2015-08-28 |
할로자임, 아이엔씨 |
Extended soluble ph20 polypeptides and uses thereof
|
US8642737B2
(en)
|
2010-07-26 |
2014-02-04 |
Baxter International Inc. |
Nucleophilic catalysts for oxime linkage
|
EP2459226B1
(en)
*
|
2009-07-27 |
2016-06-29 |
Lipoxen Technologies Limited |
Glycopolysialylation of proteins other than blood coagulation proteins
|
ES2597954T3
(en)
|
2009-07-27 |
2017-01-24 |
Baxalta GmbH |
Blood coagulation protein conjugates
|
RU2744370C2
(en)
*
|
2009-07-27 |
2021-03-05 |
Баксалта Инкорпорейтед |
Blood coagulation protein conjugates
|
US8809501B2
(en)
|
2009-07-27 |
2014-08-19 |
Baxter International Inc. |
Nucleophilic catalysts for oxime linkage
|
IN2012DN03219A
(en)
|
2009-09-17 |
2015-10-23 |
Baxter Healthcare Sa |
|
BR112012015597A2
(en)
|
2009-12-21 |
2017-01-31 |
Ambrx Inc |
modified porcine somatotropin peptides and their uses
|
MX349301B
(en)
|
2009-12-21 |
2017-07-21 |
Ambrx Inc |
Modified bovine somatotropin polypeptides and their uses.
|
US9815876B2
(en)
|
2010-03-05 |
2017-11-14 |
Omeros Corporation |
Chimeric inhibitor molecules of complement activation
|
WO2011143274A1
(en)
|
2010-05-10 |
2011-11-17 |
Perseid Therapeutics |
Polypeptide inhibitors of vla4
|
EP2595624B1
(en)
|
2010-07-20 |
2018-01-31 |
Halozyme, Inc. |
Methods of treatment or prevention of the adverse side-effects associated with administration of an anti-hyaluronan agent
|
KR101969601B1
(en)
*
|
2010-07-30 |
2019-04-17 |
박스알타 인코퍼레이티드 |
Nucleophilic catalysts for oxime linkage
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
HUE045845T2
(en)
|
2010-08-17 |
2021-12-28 |
Ambrx Inc |
Modified relaxin polypeptides and their uses
|
AR083006A1
(en)
|
2010-09-23 |
2013-01-23 |
Lilly Co Eli |
FORMULATIONS FOR THE STIMULATING FACTOR OF COLONIES OF GRANULOCITS (G-CSF) BOVINE AND VARIANTS OF THE SAME
|
EP2672958A1
(en)
|
2011-02-08 |
2013-12-18 |
Halozyme, Inc. |
Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
|
EP2720713A2
(en)
|
2011-06-17 |
2014-04-23 |
Halozyme, Inc. |
Continuous subcutaneous insulin infusion methods with a hyaluronan degrading enzyme
|
US9993529B2
(en)
|
2011-06-17 |
2018-06-12 |
Halozyme, Inc. |
Stable formulations of a hyaluronan-degrading enzyme
|
CA2840552A1
(en)
|
2011-07-01 |
2013-01-10 |
Bayer Intellectual Property Gmbh |
Relaxin fusion polypeptides and uses thereof
|
US20130071394A1
(en)
|
2011-09-16 |
2013-03-21 |
John K. Troyer |
Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use
|
SG11201401797TA
(en)
|
2011-10-24 |
2014-09-26 |
Halozyme Inc |
Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
|
PT3130347T
(en)
|
2011-12-30 |
2019-12-10 |
Halozyme Inc |
Ph20 polypeptide variants, formulations and uses thereof
|
PT2833905T
(en)
|
2012-04-04 |
2018-08-06 |
Halozyme Inc |
Combination therapy with hyaluronidase and a tumor-targeted taxane
|
AU2013204754C1
(en)
*
|
2012-05-16 |
2018-10-11 |
Takeda Pharmaceutical Company Limited |
Nucleophilic Catalysts for Oxime Linkage
|
AU2013270684B2
(en)
|
2012-06-08 |
2018-04-19 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
DK2863955T3
(en)
|
2012-06-26 |
2017-01-23 |
Sutro Biopharma Inc |
MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
|
ES2907763T3
(en)
|
2012-08-31 |
2022-04-26 |
Sutro Biopharma Inc |
Modified amino acids comprising an azido group
|
WO2014062856A1
(en)
|
2012-10-16 |
2014-04-24 |
Halozyme, Inc. |
Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
|
TW201534726A
(en)
|
2013-07-03 |
2015-09-16 |
Halozyme Inc |
Thermally stable PH20 hyaluronidase variants and uses thereof
|
ES2658039T3
(en)
|
2013-07-10 |
2018-03-08 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods for their preparation and methods of use
|
WO2015054658A1
(en)
|
2013-10-11 |
2015-04-16 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
EP3186281B1
(en)
|
2014-08-28 |
2019-04-10 |
Halozyme, Inc. |
Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
|
NZ730563A
(en)
|
2014-10-14 |
2019-05-31 |
Halozyme Inc |
Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
|
EA036697B1
(en)
|
2014-10-24 |
2020-12-09 |
Бристол-Майерс Сквибб Компани |
Modified fgf-21 polypeptides and uses thereof
|
CA3052639A1
(en)
|
2017-02-08 |
2018-08-16 |
Bristol-Myers Squibb Company |
Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
|
KR102268647B1
(en)
|
2017-06-12 |
2021-06-23 |
한국코러스 주식회사 |
A Composition comprising erythropoietin and a method of producing the same
|
CN111107870A
(en)
|
2017-06-22 |
2020-05-05 |
催化剂生物科学公司 |
Modified membrane serine protease 1(MTSP-1) polypeptides and methods of use thereof
|
US20190351031A1
(en)
|
2018-05-16 |
2019-11-21 |
Halozyme, Inc. |
Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
|
FI3849614T3
(en)
|
2018-09-11 |
2024-02-08 |
Ambrx Inc |
Interleukin-2 polypeptide conjugates and their uses
|
JP2022512746A
(en)
|
2018-10-19 |
2022-02-07 |
アンブルックス,インコーポレイテッド |
Interleukin-10 polypeptide complex, its dimer, and their use
|
KR20210110848A
(en)
|
2018-12-28 |
2021-09-09 |
카탈리스트 바이오사이언시즈, 인코포레이티드 |
Modified urokinase type plasminogen activator polypeptides and methods of use
|
US11613744B2
(en)
|
2018-12-28 |
2023-03-28 |
Vertex Pharmaceuticals Incorporated |
Modified urokinase-type plasminogen activator polypeptides and methods of use
|
BR112021015832A2
(en)
|
2019-02-12 |
2022-01-18 |
Ambrx Inc |
Compositions containing antibody-tlr agonist conjugates, methods and uses thereof
|
AU2021233909A1
(en)
|
2020-03-11 |
2022-09-29 |
Ambrx, Inc. |
Interleukin-2 polypeptide conjugates and methods of use thereof
|
AU2021327396A1
(en)
|
2020-08-20 |
2023-03-23 |
Ambrx, Inc. |
Antibody-TLR agonist conjugates, methods and uses thereof
|
WO2022212899A1
(en)
|
2021-04-03 |
2022-10-06 |
Ambrx, Inc. |
Anti-her2 antibody-drug conjugates and uses thereof
|